BioXcel Therapeutics Files 8-K on Financials
Ticker: BTAI · Form: 8-K · Filed: Mar 27, 2025 · CIK: 1720893
Sentiment: neutral
Topics: financial-condition, results-of-operations, sec-filing
Related Tickers: BTAI
TL;DR
BioXcel Therapeutics filed an 8-K on March 27, 2025, detailing financial condition and results of operations.
AI Summary
BioXcel Therapeutics, Inc. filed an 8-K on March 27, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, but no specific financial figures or operational details were provided in the excerpt.
Why It Matters
This filing indicates BioXcel Therapeutics is providing updates on its financial condition and operational results to the SEC, which is important for investors to monitor the company's performance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and does not contain any immediately apparent negative news or significant changes.
Key Players & Entities
- BioXcel Therapeutics, Inc. (company) — Registrant
- March 27, 2025 (date) — Filing Date
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided excerpt states the filing pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits,' but does not specify the actual financial figures or operational details.
When was this 8-K report filed with the SEC?
This 8-K report was filed on March 27, 2025.
What is the principal executive office address for BioXcel Therapeutics, Inc.?
The principal executive offices are located at 555 Long Wharf Drive, New Haven, CT 06511.
What is the telephone number for BioXcel Therapeutics, Inc.?
The registrant's telephone number is (475) 238-6837.
What is the Standard Industrial Classification code for BioXcel Therapeutics, Inc.?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 27, 2025 regarding BioXcel Therapeutics, Inc. (BTAI).